Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • Nurse Well-Being
    • Drug Reference Sheets
    • ONS Congress
    • Specific Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    cozy hospital room with bed and computer
    Interprofessional Issues
    Novel, Interprofessional Approach Enhances Bed Assignments for Individuals on Antineoplastic Drugs in a Hospital Setting
    August 22, 2024
    hand touching futuristic screen that represents artificial intelligence
    Nurse Empowerment
    How AI Can Support Oncology Nurses’ Spirit of Inquiry
    August 15, 2024
    person with brown clothes holding patient's hand in support on hospital bed
    Nurse Empowerment
    Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession
    July 04, 2024
    publish with ONS Voice
    Nursing Professional Development
    Publish Your First Article With ONS Voice
    March 19, 2024
    A family of nurses
    Nurse Well-Being
    When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places
    March 07, 2024
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Grief & Bereavement

    How Grief Can Impact Safety and Patient Outcomes

    Oncology nurses face some uncomfortably common truths when treating patients with cancer. Invariably—no matter how hard certain patients fight—some will die from their diseases. Patient death is a part of oncology care, and no nurse would tell you differently. But accepting and dealing with loss and grief is sometimes pushed aside in favor of stoic attitudes that some may equate with professionalism.
    November 24, 2016
    U.S. Food and Drug Administration (FDA)

    FDA Approves Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

    On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (Darzalex®, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
    November 22, 2016

    Perceived Barriers Affect Nonadherence to Breast Cancer Treatment

    Women with early-stage breast cancer who have more perceived barriers to aromatase inhibitor (AI) treatment are less likely to adhere to their treatment regimens, according to the results of a study published in Cancer.
    November 22, 2016
    Clinical Practice

    New Guidelines Suggest Radiation for More Patients With Breast Cancer

    Even women with smaller breast cancer tumors and three or fewer lymph nodes involved can benefit from radiation therapy after mastectomy, according to the results of new guidelines published.
    November 22, 2016
    Leukemia

    New Recommendations Call for Bagged Vinca Alkaloids

    The National Comprehensive Cancer Network’s (NCCNs’) Best Practice Committee has recently issued guidelines that advise healthcare providers to dilute vinca alkaloids in a mini-IV drip bag, rather than preparing and providing the agent in a syringe.
    November 16, 2016
    Breast Cancer

    Patient Factors Should Guide Breast Cancer Screening Intervals

    Mammography screening recommendations should be based on risk, rather than age, according to the results of a new study published in Annals of Internal Medicine.
    November 15, 2016
    Lung Cancer

    The Case of the Struggle to Stop Smoking

    Bonnie, a 70-year-old woman, arrives at the outpatient oncology clinic to learn about treatment options for stage IIB small cell lung cancer. During the intake process, Bonnie tells Daryl, an oncology nurse, that despite her new lung cancer diagnosis, she just can’t seem to find the willpower to quit smoking. What would you do?
    November 15, 2016
    Cancer Treatments

    FDA Approves Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    On November 10, 2016, the U.S. Food and Drug Administration approved nivolumab (Opdivo® injection, Bristol-Myers Squibb Company), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy.
    November 10, 2016
    ONS News

    NAM Elects ONS Member Bruner to 2016 Class of Leading Health Scientists

    The National Academy of Medicine (NAM), formerly the Institute of Medicine, has elected ONS member Deborah W. Bruner, RN, PhD, FAAN, to its 2016 class of leading health scientists and international members. Bruner, professor in the department of radiation oncology at Emory University and associate director of faculty membership, training, and education at the Winship Cancer Institute of Emory University, has long been recognized for her work in clinical trials and her research of sexuality after cancer therapy.
    November 08, 2016
    Breast Cancer

    Dietary Choices May Contribute to Breast Density in Overweight Women

    Overweight and obese women who maintain a Western diet may develop dense breast tissue that may increase their risk for breast cancer, according to a study published in Obstetrics and Gynecology.
    November 08, 2016
    Breast Cancer

    How Nurses Can Help Women Adhere to Oral Adjuvant Breast Cancer Treatment

    In an article in the July 2016 issue of the Oncology Nursing Forum, researchers set out to study the experience of women specifically with estrogen receptor- (ER-) positive breast cancer and what they felt helped or hindered their survivorship experience.
    November 08, 2016
    Cancer Healthcare Advocacy

    Now Is an Exciting Time for Advocacy

    In September, I had the honor to join more than 100 ONS members as we convened in Washington, DC, to advocate for issues important for cancer care and oncology nursing. The National Cancer Moonshot Initiative report had just been released, and our group was invited to the White House office building for a conversation with Vice President Biden.
    November 01, 2016
    ONS News

    ONS Makes Nurses’ Voices Heard During Hill Days

    The political stars were aligned, a rarity in today’s contentious environment, as ONS held its first organizational advocacy days in Washington, DC, in September 2016. A total of 100 oncology nurses took part in the event to carry the ONS Health Policy Agenda and legislative priority list to Capitol Hill.
    November 01, 2016
    Cancer Risk Prevention

    Cancer's Risky Business

    Although it’s impossible to predict what can lead to cancer in any individual, researchers look at data compiled over many years to make confident decisions that certain behaviors, characteristics, and factors increase the risk of developing cancer. By discussing these factors with patients, oncology nurses can potentially reduce or identify their chances of developing future cancers.
    November 01, 2016
    Genetics & Genomics

    How Do You Bridge Oncology Nurses and Genetic Counselors?

    Assessing a patient’s risk for cancer is an exciting area for collaboration between oncology nurses and genetic counselors. Oncology nurses have a very specialized skill set, and genetic counselors can complement it.
    November 01, 2016
    Breast Cancer

    Genes Linked to Breast Cancer Survival

    Researchers have found that activity in two particular genes, F12 and STC2, can predict 10-year survival from HER2-positive breast cancer. The findings were reported in Oncotarget.
    November 01, 2016
    Cancer Treatments

    FDA Approves Pembrolizumab for Treatment of Non-Small Cell Lung Cancer

    On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®, Merck & Co., Inc.) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 as determined by an FDA-approved test.
    October 25, 2016
    Breast Cancer

    Sentinel Node Dissection Sufficient for Localized Breast Cancer

    Researchers have found no significant difference in five-year locoregional recurrence or survival in women with T1/2N0M0 breast cancer who received sentinel node dissection and axillary lymph node dissection compared to sentinel node dissection only.
    October 25, 2016
    Cancer Research

    New Technique Identifies DCIS That Are Likely to Become Aggressive

    Researchers at the University of Michigan have developed a technique to predict whether ductal carcinoma in situ (DCIS) may become aggressive. The new method, called biomarker ratio imaging microscopy (BRIM), may prevent women whose cancers would never become aggressive from receiving unnecessary treatment.
    October 25, 2016
    Patient Safety

    New Computing Technology Ensures Safety for Telemedicine and Telemonitoring in Oncology Care

    As a research associate for ONS, I participated on a panel of oncology experts advising a group of undergraduate and graduate students regarding the lived experience of cancer treatment for older adults. The students, attending Carnegie Mellon University (CMU) in Pittsburgh, PA, were aspiring computer scientists taking a course called Rapid Prototyping of Computer Systems; they developed the following research question based on input from the expert panel.
    October 24, 2016
    Culture of Safety

    Become a Champion of Safety Through Error Recognition and Reporting

    Within a culture of safety, accountability for safe and ethical care is a priority. Nurses must advocate for their patients and actively prevent patient harm when faced with safety concerns. With the increasing complexity of cancer care, safety risks are always present. Errors can be life threatening, and oncology nurses must feel comfortable in their ability to recognize and report these events.
    October 20, 2016
    Cancer Treatments

    FDA Approves Olaratumab for Soft Tissue Sarcoma

    On October 19, 2016, the U.S. Food and Drug Administration granted accelerated approval to olaratumab (Lartruvo™, Eli Lilly and Company) for the treatment of patients with soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate.
    October 20, 2016
    Cancer Moonshot

    Vice President Announces Strategic Goals, New Partnerships for Cancer Moonshot

    On October 17, 2016, Vice President Joe Biden addressed President Obama and the rest of the United States as he presented the National Cancer Moonshot taskforce’s report of the work that’s been accomplished since its inception in January 2016. The report highlights a number of strategic initiatives, including the 10 recommended areas of scientific advancement the Blue Ribbon Panel identified in September.
    October 19, 2016
    Treatment Side Effects

    Know How to Properly Treat Immunotherapy Side Effects

    Oncology nurses are intimately familiar with side effects related to chemotherapy. Advice for managing chemotherapy symptoms such as fatigue, diarrhea, dyspnea, skin toxicities, and increased risk of infection can be found in ONS’s Putting Evidence Into Practice (PEP) resources. However, immunotherapy treatments often offer similar side effects that are treated very differently from those associated with traditional treatments.
    October 19, 2016
    Cancer Treatments

    FDA Approves Atezolizumab for Advanced Non-Small Cell Lung Cancer

    On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.
    October 19, 2016
    • First page « First
    • Previous page
    • …
    • Page 7
    • Page 8
    • Page 9
    • Page 10
    • Current page 11
    • Page 12
    • Page 13
    • Page 14
    • Page 15
    • …
    • Next page
    • Last page Last »

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    content['#byline_profile'].image_alt_text
    Chris Pirschel ONS Staff Writer/Producer
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Contact Us
  • Advertising
  • Newsroom
  • Conferences
  • RSS Feed
  • Sitemap
  • Legal Notices

    • Subscribe to ONS Voice Updates

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • threads
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2024 Oncology Nursing Society
    Back to Top ▲